Abstract
The lack of access to safe and effective antimicrobials for human populations is a threat to global health security and a contributor to the emergence and spread of antimicrobial resistance (AMR). The increasingly common shortages of antimicrobials are an additional threat to the emergence of AMR. While the threat of such drug shortages is most acutely experienced in low-income and middle-income settings, their consequences impact the quality and effectiveness of antimicrobials worldwide. Furthermore, there is a need for robustly conducted studies examining the impact of these increasingly prevalent shortages on patient outcomes and on the emergence and spread of AMR. In this review, we have mapped common drivers for antimicrobial shortages and propose strategies for rethinking the regulation, supply and pricing of antimicrobials to secure their sustainable access across diverse healthcare systems and to help minimise the unintended consequences of weak and ineffective supply chains. Greater government involvement in antimicrobial manufacture and supply is essential to ensure no one is left behind. Dedicated demand systems need to be developed for antimicrobials which take into consideration evolving AMR patterns, burden of diseases, pandemic events and supply and demand issues and facilitate implementation of strategies to address them. Interventions, ranging from advocacy and forecasting to public–private collaborations, new economic models and international consortia working across countries and supply chains, will help assure access to safe and effective antimicrobials to all populations around the globe and ensure that shortages no longer contribute to AMR.
Funder
Economic and Social Research Council
National Institute for Health Research, UK Department of Health in partnership with Public Health England
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference78 articles.
1. Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries
2. Ensuring access to 'access' antibiotics: an imminent consideration for sustainable antimicrobial stewardship in the developing world;Kakkar;Infect Dis,2019
3. Cefazolin shortages in the developing world: the same, but different too;Kakkar;Clin Infect Dis,2021
4. Tuberculosis drug shortage alert - Telegraph India. Available: https://www.telegraphindia.com/health/tuberculosis-drug-shortage-alert/cid/1748324 [Accessed 6 May 2021].
5. 2 orphan drugs find manufacturers in Korea. Korea biomedical review. Available: https://www.koreabiomed.com/news/articleView.html?idxno=1584 [Accessed 28 Jun 2021].
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献